Quantification of non-activated (native) complement component C9 synthesized by alveolar macrophages from patients with sarcoidosis.
Alveolar macrophages (AM) from sarcoidosis patients synthesize the functional alternative and terminal pathways of complement, and increased complement production may be one of multiple factors in the pathogenesis of sarcoidosis. We thus examined whether AM from sarcoidosis patients produced quantitatively more C9 in vitro than AM from healthy controls. AM from 16 patients with active sarcoidosis and seven healthy controls were cultured under serum-free conditions for 6, 12, 24, 48, or 72 h. A quantitative production of C9 was found in the harvested medium in 10 of 16 sarcoidosis patients. There were no detectable levels of C9 in the seven controls. Activated C9 was found in all patients and in the majority of the controls. C9 was quantified by an enzyme immunoassay based on a monoclonal antibody (M1) to non-activated C9. Our results indicate greater production of C9 by sarcoidosis AM than by their healthy counterparts.
Department of Internal Medicine, University of Trondheim, Norway.
H B
HB
Pettersen
E
E
Johnson
P
P
Garred
G
G
Hetland
S S
SS
Osen
T E
TE
Mollnes
D000328:Adult; D000911:Antibodies, Monoclonal; D001992:Bronchoalveolar Lavage Fluid; D002478:Cells, Cultured; D003186:Complement C9 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008168:Lung / Q000276:immunology; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012507:Sarcoidosis / Q000276:immunology*
D000911:Antibodies, Monoclonal; D003186:Complement C9